Perpetual Ltd bought a new stake in Becton Dickinson and Co (NYSE:BDX) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 1,100 shares of the medical instruments supplier’s stock, valued at approximately $278,000.
A number of other large investors have also recently modified their holdings of BDX. TRUE Private Wealth Advisors acquired a new position in shares of Becton Dickinson and during the second quarter valued at about $25,000. Allworth Financial LP grew its position in Becton Dickinson and by 386.4% in the 3rd quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 85 shares in the last quarter. Hexavest Inc. bought a new stake in Becton Dickinson and in the 2nd quarter worth about $28,000. Lipe & Dalton bought a new position in shares of Becton Dickinson and during the 2nd quarter valued at approximately $28,000. Finally, CX Institutional bought a new position in shares of Becton Dickinson and during the 3rd quarter valued at approximately $31,000. Institutional investors and hedge funds own 84.21% of the company’s stock.
NYSE BDX opened at $252.44 on Friday. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $264.74. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.09 and a quick ratio of 0.67. The stock has a market capitalization of $66.00 billion, a PE ratio of 22.93, a P/E/G ratio of 1.56 and a beta of 1.12. The company’s 50 day simple moving average is $253.65 and its two-hundred day simple moving average is $245.78.
The business also recently declared a quarterly dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 9th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.22%. The ex-dividend date was Friday, September 6th. Becton Dickinson and’s payout ratio is 27.97%.
In other news, Director Claire Fraser sold 1,429 shares of the stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $243.26, for a total value of $347,618.54. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Vincent A. Forlenza sold 11,532 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $260.38, for a total transaction of $3,002,702.16. Following the completion of the transaction, the chief executive officer now directly owns 218,671 shares in the company, valued at approximately $56,937,554.98. The disclosure for this sale can be found here. Insiders sold a total of 37,249 shares of company stock worth $9,616,803 in the last three months. Insiders own 0.12% of the company’s stock.
A number of research analysts have recently weighed in on BDX shares. Wells Fargo & Co increased their target price on shares of Becton Dickinson and from $270.00 to $290.00 and gave the company an “outperform” rating in a research report on Friday, September 6th. Morgan Stanley upped their price target on shares of Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 16th. Piper Jaffray Companies dropped their price target on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. ValuEngine cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Raymond James upped their price target on shares of Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a research note on Friday, June 28th. Five analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Becton Dickinson and presently has a consensus rating of “Buy” and an average target price of $266.55.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Article: How are capital gains distributions different for tax-deferred account?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.